Banner Health Launches Landmark Alzheimer’s Prevention Trial with First Participant
Event summary
- Banner Health’s Alzheimer’s Prevention Initiative (API) has randomized its first participant in a trial testing single and combo therapies for Alzheimer’s prevention.
- The trial targets 200 cognitively unimpaired and mildly impaired carriers of the PSEN1 gene mutation, with a $74.5 million grant from the National Institute on Aging.
- The study will compare Eli Lilly’s donanemab, Roche’s nivagacetor, and their combination to prevent amyloid plaque buildup.
- The trial builds on previous research with the Colombian autosomal dominant Alzheimer’s disease (ADAD) kindred, which includes 1,200 mutation carriers.
The big picture
This trial represents a significant step in Alzheimer’s prevention research, leveraging genetic insights from the Colombian ADAD kindred to test innovative therapeutic combinations. The collaboration between Banner Health, Eli Lilly, Roche, and academic institutions underscores the growing focus on early intervention strategies in neurodegenerative diseases. Success could redefine the treatment landscape for Alzheimer’s, potentially leading to broader applications beyond genetic forms of the disease.
What we're watching
- Therapeutic Efficacy
- Whether the combination of donanemab and nivagacetor proves more effective than either therapy alone in preventing Alzheimer’s progression.
- Trial Execution
- The pace at which the trial enrolls the remaining participants and maintains adherence to the study protocol.
- Market Impact
- How successful results could accelerate the development and approval of preventive Alzheimer’s therapies.
Related topics
